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AbstrAct
Aims To retrospectively determine the relative frequency 
of feline hepatobiliary diseases from biopsy specimens 
submitted to a single laboratory across a 10-year period 
and to establish whether age, sex or breed associations 
exist.
Methods Histopathological data from 154 liver biopsies 
of New Zealand cats sampled between 2008 and 2018 
were analysed. The samples were allocated to primary, 
secondary and tertiary disease categories using criteria 
established by the World Small Animal Veterinary 
Association. Breed associations were derived using ORs 
and 95% CIs. Gender and age associations were also 
evaluated.
Results The most frequently diagnosed hepatobiliary 
diseases were lymphocytic cholangitis (20 per cent), 
hepatitis (16.9 per cent), reversible hepatocellular injury 
(16.4 per cent), neutrophilic cholangitis (9.7 per cent), 
haematopoietic neoplasia (9.7 per cent), hepatocellular 
neoplasia (5.6 per cent) and cholangiocellular neoplasia 
(4.1 per cent). Burmese cats were found to be at 
significantly increased risk of both biliary and parenchymal 
diseases and Birman cats to be at significantly increased 
risk of parenchymal disease. Domestic longhair cats were 
at significantly increased risk of hepatobiliary neoplasia. 
Birman cats were at significantly increased risk of hepatitis 
while domestic shorthair cats were at significantly 
decreased risk of neutrophilic cholangitis, reversible 
hepatocellular injury and hepatitis.
Conclusions This study is the first retrospective 
examination of the relative frequency of hepatobiliary 
disease in biopsy specimens from New Zealand cats. 
Some breeds were associated with specific histopathology.
IntRoduCtIon
Infectious and inflammatory hepatobiliary 
diseases are common causes of morbidity and 
mortality in feline patients.1 Sterile inflam-
matory liver diseases are more common 
in feline patients than primary infectious 
hepatobiliary conditions,1 2 but there can 
be overlap; advanced diagnostics are often 
needed to secure a definitive diagnosis and 
therefore appropriate treatment. Bacterial 
infection is only reported in around 15 per 
cent of cats with hepatobiliary disease and 
is more commonly associated with neutro-
philic cholangitis/cholangiohepatitis.1 
Feline hepatic lipidosis has historically been 
considered the most common feline hepato-
biliary disease.3 In the last decade, however, 
emerging descriptive studies of feline hepa-
tobiliary disease outside of North America 
have begun to call into question whether 
the prevalence of feline hepatic lipidosis is 
consistent across geographically disparate 
populations of cats.4 5 Having accurate pretest 
prevalence data is important for appropriate 
use and interpretation of all diagnostic tests, 
including those of the hepatobiliary system.
The histopathological frequency of feline 
hepatobiliary disease was initially reported 
in 1996 in a cohort of cats in North America3 
and more recently the frequency has been 
reported in Japan and the UK.4 5 Similar 
studies of feline hepatobiliary disease in 
Australasia are lacking. Anecdotally, a diag-
nosis of hepatic lipidosis in cats is relatively 
uncommon in New Zealand compared with 
North America.3 Gagne et al3 published a 
study of hepatobiliary disease in 175 North 
American cats where 49 per cent of the liver 
biopsies were consistent with hepatic lipi-
dosis. A more recent study in Japan found 
neutrophilic cholangiohepatitis/cholangitis 
to account for 28.1 per cent of all feline liver 
biopsies.5 Similarly, a UK study found biliary 
disorders to be the most frequent morpholog-
ical diagnosis with neutrophilic cholangitis 
representing 20.5 per cent of feline hepatic 
biopsy samples.4 Given the geographical 
differences already documented in these 
studies it seems prudent to investigate the 
distribution of feline hepatobiliary disease 
in New Zealand. There is also a paucity of 
descriptive studies reporting feline breed and 
age predispositions to hepatobiliary disease.
The World Small Animal Veterinary Asso-
ciation (WSAVA) has provided guidelines 
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Table 1 Histopathological categorisation hierarchy for feline and canine hepatobiliary diseases according to the WSAVA 
criteria
Primary category
Vascular Biliary Parenchymal Neoplastic
Secondary and tertiary categories*
Impaired hepatic 
perfusion
Peliosis hepatis, 
atrophy, 
ischaemic 
necrosis
Biliary cystic disease Reversible 
hepatocellular injury
Cloudy 
swelling, 
steroid 
induced, 
lipidosis
Hepatocellular 
neoplasia
Hyperplasia, 
adenoma,
carcinoma
Congenital 
portosystemic 
shunt
Biliary atresia Amyloidosis Cholangiocellular 
neoplasia
Adenoma, 
carcinoma
Outflow disorders Neutrophilic 
cholangitis
Apoptosis/necrosis
Carcinoid
Disorders of portal 
hypertension
Portal vein 
obstruction, 
PHPV, AV fistula
Lymphocytic 
cholangitis
Hepatitis Acute Chronic 
Reactive Hepatoblastoma
  Destructive 
cholangitis
Abscess/granuloma
Primary vascular/
mesenchymal 
neoplasia
  Chronic cholangitis 
due to fluke 
infestation
Metabolic storage 
disease Haematopoietic 
neoplasia
Lymphoma, other
  Cholestasis
Metastatic neoplasia
*Tertiary categories are in italics where applicable.
AV, arteriovenous; PHPV, primary hypoplasia of the portal vein; WSAVA, World Small Animal Veterinary Association.
for the categorisation of canine and feline hepatobiliary 
disease and recognises four morphological groups of 
disease: vascular, biliary, parenchymal and neoplastic.6 
Although these guidelines provide an objective basis for 
allocation of histopathological findings into disease cate-
gories, their application by pathologists remains inher-
ently subjective. There may also be inconsistency in the 
adherence to these criteria by pathologists over time and 
across different laboratories.
The aim of this retrospective study was to determine 
the histopathological frequency of feline hepatobiliary 
diseases from a large sample of hepatic biopsies from 
New Zealand cats and to establish whether age, sex or 
breed associations exist.
MAteRIAls And Methods
Histopathological data from feline liver biopsies 
submitted to IDEXX Laboratories/New Zealand Veter-
inary Pathology from various primary care and referral 
centres throughout New Zealand between July 2008 
and July 2018 were retrieved using a keyword search. 
The keywords used included: liver and ‘hepat%’, the 
‘hepat%’ allowing the search to pick up any word begin-
ning with ‘hepat-’ (hepatitis, hepatopathy, hepatocel-
lular, and so on). Details recorded included breed, age, 
sex, gross and histopathological descriptions, diagnosis 
and any additional comments made by the pathologist. 
The samples were read by board-certified veterinary 
anatomical pathologists. All reports were reviewed by one 
board-certified veterinary anatomical pathologist (MH), 
and where the final diagnosis was not consistent with 
the current WSAVA guidelines, these guidelines were 
retrospectively applied to the histopathological descrip-
tion. Samples were excluded if there was no definitive 
histopathological diagnosis or if there was no evidence 
of significant hepatic pathology. If more than one diag-
nosis was made on a given liver sample, each separate 
diagnosis was included in the analysis. Each diagnosis was 
assigned to one of 24 categories according to the WSAVA 
histopathological criteria for feline hepatobiliary diseases 
which were nested under the four primary disease catego-
ries of vascular, biliary, parenchymal and neoplastic disor-
ders. The WSAVA guidelines for hepatobiliary disease in 
dogs and cats do not allocate tertiary groupings to every 
secondary histopathological category, and in our data set 
not every submission was categorised to a tertiary level 
even when such criteria were available; the tertiary cate-
gories were therefore not used for analysis (table 1).
Demographic information of the New Zealand 
cat population was derived from the New Zealand 
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Table 2 Overall distribution of feline hepatobiliary diseases
Diagnosis Cases (n)
Percentage of total 
cases (%)
Percentage of cases 
within category (%)
Biliary 68 34.9 100
  Lymphocytic cholangitis 39 20.0 57
  Neutrophilic cholangitis 19 9.7 28
  Biliary cystic disease 5 2.6 7
  Cholestasis 5 2.6 7
Parenchymal 65 33.3 100
  Hepatitis 33 16.9 51
  Reversible hepatocellular injury 32 16.4 49
Neoplastic 46 23.6 100
  Haematopoietic neoplasia 19 9.7 41
  Hepatocellular neoplasia 11 5.6 24
  Cholangiocellular neoplasia 8 4.1 17
  Metastatic neoplasia 6 3.1 13
  Neoplasia* 1 0.5 2
  Carcinoid 1 0.5 2
Vascular 16 8.2 100
  Impaired hepatic perfusion 15 7.7 94
  cPSS 1 0.5 6
Total 195 100.0 100
*Neoplasia confirmed, but further identification not possible.
cPSS, congenital portosystemic shunt.
companion animal register which includes breed, age 
and gender information for all cats that had microchips 
registered between 2008 and 2018. There were a total 
of 358 989 cats suitable for inclusion in the data from 61 
specified breeds. These data were used as a control popu-
lation against which to estimate breed prevalence and 
sex distribution in the New Zealand cat population, in 
order to interrogate the possibility of breed and sex asso-
ciations with specific hepatobiliary diseases in our sample 
population.
The proportion of diagnoses in each of the WSAVA 
categories and in each primary disease category was 
determined for the study population. The distribution of 
diagnoses among breeds was calculated at two different 
levels of diagnostic aggregation: the four primary disease 
categories and the 24 WSAVA secondary categories.
An OR was calculated for each breed in the sample 
population as well as each primary and secondary disease 
category. The OR was defined as the ratio of ‘the odds of 
a cat of a specified breed having the disease’ to ‘the odds 
of a cat from any other breed having the disease’. This is 
equivalent to the ratio of ‘the number of diseased cats of 
a given breed’ to ‘the number of diseased cats from all 
other breeds’ divided by the ratio of ‘the number of cats 
of the same given breed’ to ‘the number of cats from all 
other breeds’. A CI of the OR was calculated using Wald’s 
method7 and statistical significance was determined 
using the chi-squared test, except when the number of 
diagnoses was fewer than 5, when Fisher’s exact test was 
used. A breed association was deemed significant if the 
OR CI did not include one, with 5 per cent significance 
threshold.
An association between gender and disease (primary 
and secondary categories) was investigated with a 
chi-squared test. An association among age and diag-
nostic category was investigated with analysis of variance 
and pairwise testing using Tukey’s multiple comparison 
test. All statistical analyses were carried out using the 
statistical package R (R Core Team 2019, V.3.6.0).
Results
A total of 316 histopathology submissions were identified 
using the initial search criteria. Of this total, 101 submis-
sions were not of hepatic tissue, leaving 215 submissions 
that contained histopathological data for liver tissue. 
Twenty-four submissions were excluded as non-diagnostic 
and 37 were considered to have no hepatic pathology. 
Of the remaining 154 submissions, 33 had evidence 
of two primary liver diseases and four had evidence of 
three primary liver diseases leaving 117 with a single 
histopathological diagnosis. This generated a total of 
195 histopathological diagnoses available for evaluation. 
Table 2 summarises the distribution of histopathological 
diagnosis in this population of cats.
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Table 3 Breed associations* according to primary hepatobiliary disease classification
Category Breed Cases (n) In registry (n) OR 95% CI P value
Biliary DSH† 39 246,459 0.44 0.27 to 0.72 <0.001
  DLH 7 22,693 1.54 0.7 to 3.36 0.278
  Burmese‡ 6 10,647 2.87 1.24 to 6.64 0.01
Parenchymal DSH† 27 246,459 0.26 0.16 to 0.43 <0.001
  Burmese† 7 10,647 3.7 1.69 to 8.1 <0.001
  Birman† 7 6754 5.9 2.69 to 12.93 <0.001
  DLH 5 22,693 1.15 0.46 to 2.87 0.759
  DMH 5 30,576 0.83 0.34 to 2.08 0.697
Neoplastic DSH 31 246,459 0.58 0.3 to 1.08 0.081
  DLH‡ 7 22,693 2.31 1.04 to 5.18 0.035
Vascular DSH 10 246,459 0.48 0.18 to 1.33 0.152
*For breeds with ≥5 cases.
†Statistically significant with P<0.001.
‡Statistically significant with P<0.05.
§Statistically significant with P<0.01.
DLH, domestic longhair; DMH, domestic medium hair; DSH, domestic shorthair.
The most common biliary disease was lymphocytic chol-
angitis with 39 cases accounting for 57 per cent of biliary 
cases and 20 per cent of submissions overall. Neutrophilic 
cholangitis was the second most common biliary disease 
with 19 cases, representing 9.7 per cent of all submissions. 
Parenchymal disease was evenly distributed into hepatitis 
with 33 cases and reversible hepatocellular injury with 
32 cases, making up 16.9 and 16.4 per cent, respectively, 
of all cases. No cases of chronic hepatitis were recorded. 
Not all cases of reversible hepatocellular injury were 
further categorised to the specific type of injury (cloudy 
swelling, glycogen storage, lipidosis), but 15 cases of 
hepatic lipidosis were specifically reported, representing 
7.6 per cent of all submissions. Haematopoietic neoplasia 
was the most common neoplastic disease with 19 cases 
(41 per cent of neoplastic cases) and 9.7 per cent of cases 
overall. The majority were lymphoma with 16 cases, but 
two cases of mast cell tumour and a single case of plasma 
cell tumour were also diagnosed. Of the cholangiocel-
lular tumours, five were reported as adenoma and three 
as carcinoma. Two of the hepatocellular tumours were 
diagnosed as adenoma, five as carcinoma and four as 
hyperplasia. The vascular category comprised the fewest 
submissions with 15 cases of impaired hepatic perfusion 
and only a single case of congenital portosystemic shunt.
Breed distributions
Sixty-eight per cent of the control population were 
domestic shorthair (DSH) cats with 246,459 registered 
individuals. The most common purebred cats in the 
control population were the ragdoll with 10,768 regis-
tered individuals, Burmese cats with 10,647 registered 
individuals and Birman cats with 6754 registered individ-
uals comprising 3, 3 and 1.9 per cent of registered cats, 
respectively. Given the low numbers of purebred cats in 
our data set, breed associations were first investigated in 
the four primary histopathological categories (biliary, 
parenchymal, neoplastic and vascular), and only breeds 
with at least five cases were included (table 3).
DSH cats were at decreased risk of biliary and paren-
chymal diseases, with Burmese cats at increased risk of 
biliary and parenchymal diseases and Birman cats at 
increased risk of parenchymal disease. Domestic long-
hair cats were at increased risk of neoplasia. Breed asso-
ciations were then investigated in the five most frequent 
secondary histopathological categories for all breeds with 
at least two cases (table 4).
Lymphocytic cholangitis was the most common diag-
nosis with Burmese and Siamese cats at increased risk. 
Hepatitis was the next most common diagnosis with 
Birman and Burmese cats shown to be at increased risk, 
whereas DSH cats were at reduced risk. The third most 
common diagnosis was reversible hepatocellular injury 
where DSH cats were at reduced risk. The fourth most 
common diagnosis was neutrophilic cholangitis; DSH 
cats were again at a reduced risk while Persian cats and 
Sphynx were at an increased risk. The fifth most common 
diagnosis was haematopoietic neoplasia; no breed associ-
ations were identified.
Age and sex
The ages of cats in each primary diagnosis group differed 
significantly (P<0.001) as seen in table 5.
Cats with a primary diagnosis of neoplasia were signifi-
cantly older (median of 13 years) than cats with a paren-
chymal or vascular primary diagnosis (P=0.003 and 
P=0.004, respectively). Males and females were equally 
represented in each diagnostic category (table 5) and 
there was no significant difference in gender count 
across either primary diagnoses or secondary diagnoses 
(P=0.351 and P=0.786, respectively). Small numbers 
 o
n
 O
ctober 5, 2019 by guest. Protected by copyright.
http://vetrecordopen.bmj.com/
Vet R
ec O
pen: first published as 10.1136/vetreco-2019-000367 on 3 O
ctober 2019. Downloaded from
 
Open access
5Fluen T, et al. Vet Rec Open 2019;6:e000367. doi:10.1136/vetreco-2019-000367
Ta
b
le
 4
 
B
re
ed
 a
ss
oc
ia
tio
ns
* 
ac
co
rd
in
g 
to
 s
ec
on
d
ar
y 
he
p
at
ob
ili
ar
y 
d
is
ea
se
 c
la
ss
ifi
ca
tio
n
D
ia
g
no
si
s
B
re
ed
C
as
es
 (n
)
In
 r
eg
is
tr
y 
(n
)
O
R
95
%
 C
I
P
 v
al
ue
Ly
m
ph
oc
yt
ic
 c
ho
la
ng
iti
s
DS
H
26
24
6,
45
9
0.
60
0.
31
 to
 1
.1
7
0.
13
1
Bu
rm
es
e†
4
10
,6
47
3.
33
1.
18
 to
 9
.3
7
0.
04
DL
H
4
22
,6
93
1.
5
0.
53
 to
 4
.2
2
0.
35
4
Si
am
es
e†
2
25
02
6.
88
1.
66
 to
 2
8.
56
0.
03
7
He
pa
tit
is
DS
H‡
10
24
6,
45
9
0.
16
0.
07
 to
 0
.3
3
<
0.
00
1
Bi
rm
an
‡
5
67
54
8.
7
3.
36
 to
 2
2.
53
<
0.
00
1
Bu
rm
es
e†
4
10
,6
47
4.
2
1.
48
 to
 1
1.
98
0.
02
DL
H
3
22
,6
93
1.
38
0.
42
 to
 4
.5
2
0.
48
7
DM
H
3
30
,5
76
0.
99
0.
3 
to
 3
.2
7
1
Ra
gd
ol
l
2
10
,7
68
71
.3
7
17
.0
1 
to
 2
99
.5
5
0.
28
6
Re
ve
rs
ib
le
 h
ep
at
oc
el
lu
la
r 
in
ju
ry
DS
H§
17
24
6,
45
9
0.
35
0.
18
 to
 0
.7
0.
00
2
Bu
rm
es
e
3
10
,6
47
3.
03
0.
92
 to
 9
.9
6
0.
08
8
BS
H
2
14
5
5.
22
1.
25
 to
 2
1.
85
0.
06
2
DM
H
2
30
,5
76
0.
64
0.
15
 to
 2
.5
7
0.
76
5
Bi
rm
an
2
67
54
0.
64
0.
15
 to
 2
.6
7
0.
14
4
DL
H
2
22
,6
93
3.
12
0.
75
 to
 1
3.
06
1
Ne
ut
ro
ph
ili
c 
ch
ol
an
gi
tis
DS
H‡
9
24
6,
45
9
0.
17
0.
07
 to
 0
.4
3
<
0.
00
1
DL
H
2
22
,6
93
1.
41
0.
32
 to
 6
.0
8
0.
65
5
Pe
rs
ia
n†
2
38
90
8.
77
2.
03
 to
 3
7.
99
0.
02
6
Sp
hy
nx
‡
2
27
6
12
6.
04
28
.9
8 
to
 5
48
.1
6
<
0.
00
1
Ha
em
at
op
oi
et
ic
 n
eo
pl
as
ia
DS
H
13
24
6,
45
9
0.
51
0.
19
 to
 1
.3
3
0.
15
8
DL
H
3
22
,6
93
2.
32
0.
68
 to
 7
.9
8
0.
16
5
*F
or
 b
re
ed
s 
w
ith
 ≥
2 
ca
se
s.
†S
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t 
w
ith
 P
<
0.
05
.
‡S
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t 
w
ith
 P
<
0.
00
1.
B
S
H
, B
rit
is
h 
sh
or
th
ai
r;
 D
LH
, d
om
es
tic
 lo
ng
ha
ir;
 D
M
H
, d
om
es
tic
 m
ed
iu
m
 h
ai
r;
 D
S
H
, d
om
es
tic
 s
ho
rt
ha
ir.
 o
n
 O
ctober 5, 2019 by guest. Protected by copyright.
http://vetrecordopen.bmj.com/
Vet R
ec O
pen: first published as 10.1136/vetreco-2019-000367 on 3 O
ctober 2019. Downloaded from
 
Open access
6 Fluen T, et al. Vet Rec Open 2019;6:e000367. doi:10.1136/vetreco-2019-000367
Table 5 Age and gender summary of feline hepatobiliary diseases
Age (years) Gender
Min Q1 Mean Median Q3 Max F:M:U
Biliary 0.25 6 9.66 10 13 19 31:35:2
  Biliary cystic disease 6.00 14 14.80 17 18 19 2:3:0
  Cholestasis 9.00 9 9.8 10 10 11 4:1:0
  Lymphocytic cholangitis 3.00 8 9.97 10 13 17 17:21:1
  Neutrophilic cholangitis 0.25 5 7.54 7 10 14 8:10:1
Parenchymal 0.27 4.5 8.66 10 13 16 35:29:1
  Hepatitis 0.27 2.75 8.20 9.5 13 16 18:15:0
  Reversible hepatocellular injury 0.50 7 9.13 10 13 16 17:14:1
Neoplastic 3.00 10 11.73 13 14 18 22:24:0
  Carcinoid 11.00 11 11.00 11 11 11 0:1:0
  Cholangiocellular neoplasia 5.00 10.5 11.38 12 14.25 15 4:4:0
  Haematopoietic neoplasia 4.00 10 12.17 13 15.75 18 10:9:0
  Hepatocellular neoplasia 5.00 10.5 11.55 13 13.5 17 4:7:0
  Metastatic neoplasia 3.00 13.25 12.33 14 14.75 15 3:3:0
  Neoplasia* 6.00 6 6.00 6 6 6 1:0:0
Vascular 0.25 1.5 7.14 7 12 15 4:10:2
  cPSS 1.00 1 1.00 1 1 1 0:1:0
  Impaired hepatic perfusion 0.25 2.75 7.58 8 12 15 4:9:2
Grand total 0.25 6 9.62 10 13 19 92:98:5
*Neoplasia confirmed, but further identification not possible.
cPSS, congenital portosystemic shunt; F, Female entire and neutered cats; M, Male entire and neutered cats; Q1, first quartile; Q3, third 
quartile; U, Unknown gender status.
precluded the analysis of age and gender distributions 
between breeds.
dIsCussIon
This is the first study to describe the frequency of hepa-
tobiliary diseases in New Zealand cats based on histo-
pathological submissions. Biliary and parenchymal disor-
ders were the most common primary histopathological 
classifications in this study population with lymphocytic 
cholangitis being the most common diagnosis overall. 
Although reversible hepatocellular injury was reported 
in a number of cases, hepatic lipidosis was only reported 
in a minority of individuals. These results are similar to 
the findings in a population of UK cats where biliary and 
parenchymal disorders made up the majority of submis-
sions.4 However, in the UK population of cats, neutro-
philic cholangitis was the most frequent hepatobiliary 
disease comprising 20.5 per cent of all cases whereas 
lymphocytic cholangitis only comprised 6.8 per cent.4 
Hirose et al5 reported neutrophilic cholangiohepatitis 
as the most common non-proliferative liver disease in a 
Japanese population of cats.
Haematopoietic neoplasia was the most common 
hepatic neoplasm in this study population of cats. Hepato-
cellular tumours were the most common primary hepatic 
neoplasm followed by cholangiocellular tumours. This 
result is similar to what was found by Bayton et al4, but 
is in contrast to earlier reports of feline primary hepatic 
neoplasia where cholangiocellular tumours were the 
most commonly reported primary hepatic neoplasm.8–10 
Within the cholangiocellular tumours, adenomas were 
more common in this population of cats than carcinoma, 
similar to what was found by Bayton et al.4 Within the 
hepatocellular tumours, carcinoma was more common 
than adenoma, again similar to the results of a previous 
study4 and in contrast to the preceding literature which 
reports hepatocellular adenoma to be more common 
than hepatocellular carcinoma in cats.10
A broad evaluation of sex and age did not reveal any 
significant sex predilections, but cats diagnosed with 
neoplasia were significantly older than cats with paren-
chymal or vascular diseases. This is not surprising given 
the incidence of neoplasia generally increases as a func-
tion of age due to the longer exposure to external carcin-
ogens, prolonged influence of inflammatory diseases and 
cumulative mutations necessary for the development of 
cancer.11
When breed analysis was performed across the four 
primary hepatobiliary disease categories for breeds with 
at least five cases, this study found Burmese cats to be 
at significantly increased risk of both biliary and paren-
chymal diseases and Birman cats to be at significantly 
 o
n
 O
ctober 5, 2019 by guest. Protected by copyright.
http://vetrecordopen.bmj.com/
Vet R
ec O
pen: first published as 10.1136/vetreco-2019-000367 on 3 O
ctober 2019. Downloaded from
 
Open access
7Fluen T, et al. Vet Rec Open 2019;6:e000367. doi:10.1136/vetreco-2019-000367
increased risk of parenchymal disease. These results are 
similar to those identified by a UK study where Burmese 
cats were found to be at increased risk of neutrophilic 
cholangitis and reactive hepatitis and Birman cats were 
at increased risk of reactive hepatitis.4 DSH cats were at 
a significantly decreased risk of biliary and parenchymal 
diseases which again aligns with data from a UK popula-
tion of cats.4
The subsequent breed analysis across the secondary 
hepatobiliary disease categories for breeds with at least 
two cases identified a number of statistically significant 
breed associations in Burmese, Birman, DSH, Persian, 
Siamese and Sphynx cats. However, with the exception of 
the DSH and Birman cats, these breed associations were 
based on less than five cases per breed. Despite the statis-
tical significance achieved in this analysis the biological 
significance of breed associations based on so few cases is 
tenuous. As these breed associations are similar to those 
reported in other descriptive studies they warrant further 
investigation.
Birman cats were found to be at significantly increased 
risk of hepatitis which is similar to a UK study where 
Birman cats were at significantly increased risk of reactive 
hepatitis.4 In the present study it was not always reported 
by the pathologist whether a diagnosis of hepatitis was 
acute, chronic or reactive, thus they were grouped under 
the secondary diagnostic category of hepatitis. This was 
primarily due to the inconsistent application of the 
WSAVA criteria, in particular to the description and 
subsequent tertiary categorisation of hepatitis. However, 
it is important to note there was not a single diagnosis 
of chronic hepatitis in this population of cats similar to 
reports from the UK (2.4 per cent) and Japan (6.3 per 
cent), where this was an infrequent diagnosis.4 5 DSH 
cats were at significantly decreased risk of neutrophilic 
cholangitis, reversible hepatocellular injury and hepa-
titis. Again, this was similar to a UK study where DSH cats 
were at decreased risk of neutrophilic cholangitis, reac-
tive hepatitis and reversible hepatocellular injury.4
Early descriptions of neutrophilic cholangitis/chol-
angiohepatitis reported it as a syndrome of aged cats,12 
whereas lymphocytic cholangitis was typically found in 
younger cats,13 a similar pattern was observed by Hirose 
et al.5 Other studies found the opposite distribution, and 
described lymphocytic cholangitis as a disease of older 
cats, and neutrophilic cholangitis as one of middle-aged 
and younger cats.1 4 The current study, similar to Bayton 
et al’s4 study, found cats with neutrophilic cholangitis to 
be younger than those with lymphocytic cholangitis and 
this warrants further investigation. One confounding 
factor in this and other studies is the failure to distinguish 
between acute and chronic neutrophilic cholangitis 
which Callahan Clark et al1 described as having signifi-
cantly different ages of onset. Thus, depending on the 
population of cats being sampled, and the existence of 
age-related comorbidities that may preclude liver biopsy, 
the older cats with chronic neutrophilic cholangitis may 
not be fairly represented in some studies.
The low prevalence of hepatic lipidosis reported in the 
UK (3.2 per cent) and Japan (4.4 per cent) compared with 
that reported in North America (49.9 per cent) has been 
suggested to be due to breed, dietary or other environ-
mental differences; however, the underlying pathophysi-
ology of the disease remains incompletely understood.3–5 
Recent literatures investigating body condition of 
domestic cats have found similar rates of feline obesity in 
New Zealand, France, UK and North America of 2.6–7.8 
per cent, suggesting that obesity prevalence alone is not 
driving the increased frequency of hepatic lipidosis in 
North American cats.14–17 This is in contrast to Japanese 
cats, where a recent descriptive study reported 42 per 
cent of domestic cats in Japan to be obese.18 However, 
the cats in these studies may not accurately represent 
the populations of cats in the hepatic histopathological 
surveys either geographically or temporally. Also, it is not 
possible to distinguish between primary and secondary 
hepatic lipidosis histopathologically, and as the latter is 
not as closely associated with obesity, consideration of the 
body condition of the sampled population may not be 
relevant.
Triaditis is a syndrome of inflammatory disease in cats 
affecting three principal organ systems: the gastrointes-
tinal tract, the hepatobiliary system and the pancreas.19 
A recent review has explored the causative relationship 
between inflammatory bowel disease (IBD) and the 
development of cholangitis, suggesting intestinal inflam-
mation is the primary disease process which through 
various mechanisms leads to the development of both 
lymphocytic and neutrophilic cholangitis.19 Purebred 
cats have been suggested to be at increased risk of 
IBD.20 21 If the prevalence of IBD is significantly higher 
in cats with cholangiohepatitis,22 the breed associations 
seen in hepatobiliary disease in New Zealand and the UK 
may be significantly influenced by breeds with concur-
rent predispositions to IBD. Breed associations should be 
further investigated with studies integrating biopsy data 
from the liver and gastrointestinal tract of a wide cross 
section of cat breeds.
The limitations of this study include the small sample 
size and limited representation of each breed, meaning 
some breed associations may have been missed. In partic-
ular, the use of OR may not allow for the identification 
of decreased risk in individuals which are infrequently 
represented in a given population sample. The deriva-
tion of breed associations according to secondary hepa-
tobiliary disease classifications identified a number of 
breeds as being at significantly increased risk of partic-
ular hepatobiliary diseases; however, these ORs were 
based on very small numbers of cats. The identification 
of disease risk based on such a small sample size should 
prompt further research into these potential breed asso-
ciations rather than making conclusions about disease 
prevalence. The control population of cats is taken from 
the New Zealand Companion Animal Registry and this 
large sample of cats is the best available approximation of 
the overall feline breed distributions in New Zealand, but 
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may not necessarily represent the distribution of breeds 
from which the histopathology samples were taken and 
from the New Zealand cat population as a whole. The 
argument may be that purebred cats are dispropor-
tionately microchipped and registered compared with 
the domestic breeds, possibly due to a perception of 
‘increased’ value of these animals. However, one may 
consider the same factors that influence the over-rep-
resentation of purebred cats in microchip registries 
are influencing their presentation to veterinarians for 
invasive and costly interventions, hence the bias may 
be applied similarly to both populations of cats. Not all 
histopathological samples were allocated a hepatobiliary 
disease category according to the WSAVA guidelines. 
Where this was the case, a disease category was applied 
retrospectively to the histopathological description in 
accordance with the WSAVA guidelines. This process 
was conducted by a board-certified anatomical patholo-
gist (MH). Given the retrospective nature of the study, 
further clinicopathological information about each case, 
which would be of particular relevance to helping iden-
tify variables that may confound the breed associations, 
was not available.
This study adds to the developing literature describing 
the frequency of feline hepatobiliary disease and reveals 
both similarities and differences between geographically 
disparate populations of cats which may be important for 
efficient diagnostic evaluation of cats with clinical signs of 
hepatobiliary disease. This study has contributed to the 
growing evidence of breed associations for feline hepato-
biliary diseases as well as identifying a number of breeds 
worthy of further investigation.
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